Brainstorm Cell Therapeutics Property, Plant & Equipment

The latest PP&E for BCLI is $260K as of June 2026. That compares with $830K in the prior-year period — down 68.8% year over year. Investors often review this figure alongside Brainstorm Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BCLI's PP&E moved from $830K to $260K — a 68.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brainstorm Cell Therapeutics's operating scale or balance-sheet position.

A PP&E figure of $260K for BCLI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BCLI's PP&E ($260K), review year-over-year change from $830K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Brainstorm Cell Therapeutics's PP&E against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.